Most bought biotechnology stocks in Q3 2025
See which Biotechnology stocks institutional investors increased the most in Q3 2025, measured as net growth in reported share positions from Q2 2025 into Q3 2025. Notable additions at the top of this list include MERUS N V (MRUS). These rankings are based on SEC 13F filings from the investors we track.
Explore more:
| Symbol | Name | Net shares | Net value | New | Added | Trimmed | Sold out | Holding now |
|---|---|---|---|---|---|---|---|---|
| MRUS | MERUS N V | 5,626 | $772.09K | 0 | 1 | 0 | 0 | 1 |
Frequently asked questions about Most bought biotechnology stocks in Q3 2025
What are the most bought Biotechnology stocks in Q3 2025?
The most bought biotechnology stocks in Q3 2025 are those with the largest increase in reported share counts across tracked institutional investors compared to Q2 2025, based on SEC 13F filings.
Which biotechnology stocks did institutional investors added to the most in Q3 2025?
Among the managers we track, net additions were largest in companies such as MERUS N V (MRUS), based on aggregated 13F data.
How is institutional buying calculated?
Buying is calculated by summing the net increase in shares reported by tracked investors between two consecutive quarterly 13F snapshots (compared to Q2 2025).
Does this include all institutional owners?
These rankings are based on a subset of tracked institutional investors who file SEC 13F reports. While not exhaustive, the dataset includes many of the largest and most influential funds.
Are these trades real-time?
No. 13F filings are reported quarterly and may be delayed by up to 45 days. The data reflects positions at the end of the reporting period, not real-time trading activity.